Stem RX Bioscience Solution Pvt Ltd hold awareness program on stem cell therapy
By: nmtvindia
View original post here:
Stem RX Bioscience Solution Pvt Ltd hold awareness program on stem cell therapy - Video
Okyanos Heart Institute Live on 850 WFTL: Adult Stem Cell Therapy for Heart Disease
Okyanos #39; Chief Medical Officer Dr. Howard (Bo) Walpole and Chief Science Officer sat down with Karen Curtis at 850 WFTL in Ft. Lauderdale to discuss the promise of adult stem cell therapy as...
By: Okyanos Heart Institute
See the rest here:
Okyanos Heart Institute Live on 850 WFTL: Adult Stem Cell Therapy for Heart Disease - Video
Professor John Rasko on SBS Insight
Royal Prince Alfred Hospital #39;s Director of Cell and Molecular Therapies, Professor John Rasko, was invited as a guest on SBS Insight #39;s special on stem cell medicine.
By: SydneyLHD
Read more:
Professor John Rasko on SBS Insight - Video
There's no good time for a public agency to be embroiled in a conflict-of-interest scandal, but this is an especially delicate time for California's stem cell agency.
The California Institute for Regenerative Medicine, as the program is known formally, is on track to finish doling out its $3 billion in funding from the state's voters as soon as 2017. Its original sponsor, Northern California real estate developer Robert Klein II, has been quoted talking about another $5-billion infusion, perhaps via the 2016 ballot.
Any such effort will refocus attention on the program board's inherent conflicts of interest, which were baked in by the terms of Proposition 71, Klein's 2004 ballot initiative that created CIRM and funded it through a bond issue. The prestigious Institute of Medicine in a 2012 report found these conflicts to lead to questions about "the integrity and independence of some of CIRM's decisions."
And now here comes another case. This one involves CIRM former President Alan Trounson, an Australian biologist who left the agency on June 30 and joined the board of one of its highest-profile financial partners a mere seven days later. Trounson's new employer, Stem Cells Inc., is the recipient of a nearly $20-million loan for Alzheimer's research.
CIRM says Trounson's quick move to Stem Cells Inc., where he'll receive a stipend of at least $90,000 a year, is legally "permissible." But officials there acknowledge they were blindsided; the agency learned about Trounson's new position from the company's press release.
Afterward, CIRM rushed out a statement acknowledging that Trounson's appointment to the board of a CIRM loan recipient "creates a serious risk of a conflict of interest." The agency says it will place the relationship between CIRM and the company under "a full review." Administrators reminded Trounson, board members and agency staff that state law bars him from communicating with them on any administrative matter involving Stem Cells Inc. The company declined to comment.
The relationship already reeked of cronyism. As we reported in 2012, the Newark, Calif.-based firm's co-founder, Irving Weissman, director of Stanford University's Institute for Stem Cell Biology and Regenerative Medicine, had been one of the most prominent and outspoken supporters of Proposition 71.
He's also a leading recipient of CIRM funding, listed as the principal investigator on four Stanford grants totaling nearly $35 million. CIRM contributed $43.6 million toward the construction of his institute's $200-million research building at the Stanford campus. Weissman and his wife, Ann Tsukamoto, owned nearly 380,000 shares of the firm as of last April, according to a corporate disclosure. Tsukamoto is one of the company's top executives; Weissman is a board member.
Trounson's move comes as CIRM must begin looking to the future, but any discussions about extending the agency's life span will have to address the flaws created by Proposition 71. Among them is the program's very structure, and even its scientific goals.
Klein's ballot proposition exempts CIRM from virtually any oversight or accountability. Each of the 29 governing board members has to be associated with a California public or private research institution or company, or an advocacy group for patients of one disease or another. The qualifications for board chairman are so specific they initially yielded a single credible candidate: Bob Klein.
Read the rest here:
Conflicts of interest pervasive on California stem cell board
Insight: Stem Cells -- Kerri, Kristy and Jodi
Kerri Pottharst, Kristy Cruise and Jodi Russell reveal why they are choosing to have stem cell treatment to help with their illnesses. Catch the full episode...
By: Insight SBS
Visit link:
Insight: Stem Cells -- Kerri, Kristy and Jodi - Video
Before the Treatment-XiaoYe -Cerebral Palsy (Male, 4 years old) - 2011
Name: XiaoYe Gender: Male Age: 4 years old Nationality: China Diagnosis: Cerebral Palsy XiaoYe, 4- year-old male, was diagnosed as Cerebral Palsy due to his retardation in both his motor and...
By: Stem Cells
Go here to see the original:
Before the Treatment-XiaoYe -Cerebral Palsy (Male, 4 years old) - 2011 - Video
After the Treatment-XiaoYe -Cerebral Palsy (Male, 4 years old) - 2011
Name: XiaoYe Gender: Male Age: 4 years old Nationality: China Diagnosis: Cerebral Palsy XiaoYe, 4- year-old male, was diagnosed as Cerebral Palsy due to his retardation in both his motor and...
By: Stem Cells
Go here to see the original:
After the Treatment-XiaoYe -Cerebral Palsy (Male, 4 years old) - 2011 - Video
Before the fourth course of transplantation-Wu Yanyi - Cerebral Palsy (Male, 6 years old) 2008
Name: Wu Yanyi Gender: Male Age: 6 years old Nationality: China Diagnosis: Cerebral Palsy Wu Yanyi, Male, 6 years old, comes from Yingshan city in Hubei province. Preterm birth and was diagnosed...
By: Stem Cells
Read more from the original source:
Before the fourth course of transplantation-Wu Yanyi - Cerebral Palsy (Male, 6 years old) 2008 - Video
Before the first course of transplantation-Wu Yanyi - Cerebral Palsy (Male, 6 years old) 2008
Name: Wu Yanyi Gender: Male Age: 6 years old Nationality: China Diagnosis: Cerebral Palsy Wu Yanyi, Male, 6 years old, comes from Yingshan city in Hubei province. Preterm birth and was diagnosed...
By: Stem Cells
Insight: S2014 Ep22 Stem Cells
Desperate Australians are turning to controversial, unproven stem cell treatments for a whole range of illnesses. They say they #39;re tired of waiting for the long process of clinical trials to...
By: Insight SBS
Read this article:
Insight: S2014 Ep22 Stem Cells - Video
Before the second course of transplantation- Xiao Zhang - Cerebral Palsy (male, 9 years old) - 2012
Name: Xiao Zhang Gender: Male Age: 9 years old Nationality: China Diagnosis: Cerebral Palsy Xiao Zhang, Male, 9 years old. He was diagnosed with cerebral palsy due to pathologic jaundice when...
By: Stem Cells
Follow this link:
Before the second course of transplantation- Xiao Zhang - Cerebral Palsy (male, 9 years old) - 2012 - Video
Regenocyte Stem cells vs Heart transplant - Stem Cells Win!
Ed was faced with a weak heart in need of a transplant. Using his own stem cells Dr Zannos Grekos and Regenocyte treated him and now his heart is back to normal. Ed is playing basketball again.
By: Regenocyte
Here is the original post:
Regenocyte Stem cells vs Heart transplant - Stem Cells Win! - Video
Lessons Learned from Clinical Trials with Stem Cells
Roberto Bolli, MD, FAHA, reviews some of the latest advances and lessons learned from clinical trials with stem cells which he discussed at greater length in a presentation for BCVS 2014 in Las Vegas.
By: AHAScienceNews
Read the original:
Lessons Learned from Clinical Trials with Stem Cells - Video
I-DNA Phyto Stem Cell Therapy Miracle - Lily Khoo Testimonial
3 3 weeks, improving eye sight, skin tightening, solving triangular eyes...
By: I-DNA DEER PLACENTA SINGAPORE ORIGINAL
Continue reading here:
I-DNA Phyto Stem Cell Therapy Miracle - Lily Khoo Testimonial - Video
Paul Laikind, CEO of ViaCyte, which is making a treatment for diabetes from human embryonic stem cells.
In an historic announcement for the stem cell field, San Diego's ViaCyte said Thursday it has applied to start human clinical trials of its treatment for Type 1 diabetes.
ViaCyte grows replacement insulin-producing cells from human embryonic stem cells. The cells are packaged while maturing in a semi-permeable device and implanted. In animal trials, the cells produce insulin, relieving diabetes.
Now the company proposes to take what could be a cure for diabetes into people. ViaCyte has asked to begin a Phase 1/2 clinical trial, which would assess both safety and efficacy of its product. ViaCyte is targeting Type 1 diabetes, in which the insulin-producing cells are destroyed. Patients require multiple injections of insulin daily to survive.
The announcement is good news for California's stem cell agency, the California Institute for Regenerative Medicine. The agency has awarded nearly $39 million to ViaCyte to ready its device for human use.
Paul Laikind, ViaCytes chief executive, said if all goes smoothly, the first patients will be treated in August or September. Based on animal studies, it will take a few months to see results, and just a few patients will be treated at first.
CIRM itself, funded with $3 billion in state bond funds, has come under pressure to show results from its work. The money is projected to run out in 2017. Some supporters of the agency have proposed launching a new initiative to continue funding.
"This is a great example of how the investment that the voters made in creating CIRM is beginning to move from labs to patients," said Joe Panetta, a member of CIRM's governing board and chief executive of Biocom, the San Diego-based life science trade group. ""There are at least a dozen other clinical trials in progress. This is good for CIRM and San Diego."
Jonathan Thomas, chairman of CIRM's governing board, called the filing "a big step in developing therapies for Type 1 diabetes."
"The project is one that has been front and center for us for six years," Thomas said. "As a principal funder of Viacyte since 2008, we are delighted that they have taken this major step towards getting a Type 1 Diabetes therapy to patients."
Phoenix, AZ (PRWEB) July 17, 2014
Arizona Pet Vet Family of Animal Hospitals is hosting San Diego, California based Regenerative Veterinary Medicine company, Vet-Stem, Inc., for a summer session of RACE approved Credentialing Courses and wet-labs on stem cell therapy. AZ Pet Vets Family of 17 Animal Hospitals has been offering Vet-Stems Regenerative Cell Therapy to its small animal patients since 2010, and continuously strives to educate their team members on cutting-edge services like stem cell therapy.
Since Vet-Stems last training session with AZ Pet Vet in the summer of 2013 the number of pets diagnosed with arthritis has increased as much as an estimated 13% say industry sources. As many as 65% of dogs between the ages of 7 and 11 years old will be inflicted with some degree of arthritis. For certain specific breeds the percentage is as high as 70%, with an additional estimated 7% remaining undiagnosed. AZ Pet Vets Family of Animal Hospitals equips their veterinarians with a complete package of services to help diagnose and treat dogs that are suffering pain or inflammation from osteoarthritis or polyarthritis. Stem cell therapy is one of these services, most commonly used to help decrease inflammation, help with the pain of osteo or polyarthritis, as well as other joint or ligament issues, and muscle injuries.
Vet-Stems Corey Orava, DVM will be leading a series of daily training sessions which include a RACE (Registry of Approved Continuing Education from the American Association of Veterinary State Boards) approved credentialing course, and the ability to consult on potential stem cell therapy cases with current patients of AZ Pet Vets Family of Animal Hospitals. Each of these sessions will help veterinarians and their staff to learn the ins and outs of stem cell therapy, as well as benefit from a hands-on experience to bring the best care to their patients and pet owners. Under the mentorship of Dr. Orava all of the 17 AZ Pet Vet Animal Hospitals will have the potential to collect fat and inject stem cells on qualifying pet patients.
AZ Pet Vet is a family of 17 animal hospitals with one vision: to provide the best comprehensive care for their highly valued patients. Whether it be routine wellness, or other type of medical care, AZ Pet Vet provides loving care and treatment for pets. As animal lovers and pet owners, they understand the connection owners have with your pet. The doctors and staff at each hospital strive to build a long term relationship with their client families and their pets, always making recommendations in the pets best health interest. The AZ Pet Vet Family of Animal Hospitals offer complete veterinary care from wellness, to vaccines, spays and neuters, dental, surgical and now regenerative medicine. Their animal hospital locations can be easily found at http://www.arizonapetvet.com/.
Since its formation in 2002, Vet-Stem, Inc. has endeavored to improve the lives of animals through regenerative medicine. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem pioneered the use of regenerative stem cells for horses, dogs, cats, and some exotics. In 2004 the first horse was treated with Vet-Stem Regenerative Cell Therapy for a tendon injury that would normally have been career ending. Ten years later Vet-Stem celebrated its 10,000th animal treated, and the success of establishing stem cell therapy as a proven regenerative medicine for certain inflammatory, degenerative, and arthritic diseases. As animal advocates, veterinarians, veterinary technicians, and cell biologists, the team at Vet-Stem tasks themselves with the responsibility of discovering, refining, and bringing to market innovative medical therapies that utilize the bodys own healing and regenerative cells. For more information about Vet-Stem and Regenerative Veterinary Medicine, visit http://www.vet-stem.com or call 858-748-2004.
DR ANDREW J ROCHMAN: ON STEM CELL THERAPY
By: Len Promoter
See more here:
DR ANDREW J ROCHMAN: ON STEM CELL THERAPY - Video
Contact Information
Available for logged-in reporters only
Newswise Researchers at the National Institutes of Health have developed a technique that will speed up the production of stem-cell derived tissues. The method simultaneously measures the expression of multiple genes, allowing scientists to quickly characterize cells according to their function and stage of development. The technique will help the researchers in their efforts to use patients skin cells to regenerate retinal pigment epithelium (RPE)a tissue in the back of the eye that is affected in several blinding eye diseases. It will also help the scientists search for drugs for personalized treatments.
Progress in stem cell-based therapies has been limited by our capacity to authenticate cells and tissues, said Kapil Bharti, Ph.D., a Stadtman Investigator in the Unit on Ocular and Stem Cell Translational Research at the National Eye Institute (NEI), a part of NIH. This assay expands that capacity and streamlines the process.
The assay was described in a recent issue of Stem Cells Translational Medicine.
The RPE is a single layer of cells that lies adjacent to the retina, where the light-sensitive photoreceptors commonly called rods and cones are located. The RPE supports photoreceptor function. Several diseases cause the RPE to break down, which in turn leads to the loss of photoreceptors and vision.
The stem cells Dr. Bharti is using to make RPE are induced pluripotent (iPS) stem cells, which are produced by reverting mature cells to an immature state, akin to embryonic stem cells. iPS cells can be derived from a patients skin or blood cells, coaxed into other cell types (such as neurons or muscle), and in theory, re-implanted without causing immune rejection.
To verify the identity of RPE made from iPS cells, scientists use microscopy to ensure the tissue looks like RPE and physiological assays to ensure the tissue behaves like RPE. They also use a technique called quantitative RT-PCR to measure the expression of genes that indicate ongoing cell development and function. For example, expression of the gene SOX2 is much higher in iPS cells than mature RPE.
But quantitative RT-PCR only permits the simultaneous measurement of a few genes per sample. Dr. Bharti teamed up with Marc Ferrer, Ph.D., of NIHs National Center for Advancing Translational Sciences (NCATS) to develop a multiplex assaya method for simultaneously measuring multiple genes per RPE sample in a highly automated fashion. The assay is based on a commercially available platform from the biotech company Affymetrix. In the assay, tiny snippets of DNA tethered to beads are used to capture RNA moleculescreated when genes are expressed by cells in the RPE sample. Once captured, the RNA from distinct genes is labeled with a fluorescent tag.
Starting with cells from a skin biopsy, the researchers generated iPS-derived RPE and then measured the expression of eight genes that are markers of development, function, and disease. They measured RNA levels of each gene one at a time using quantitative RT-PCR and then all genes simultaneously using the multiplex assay. When compared, the results correlated.
See the rest here:
Gene Profiling Technique to Accelerate Stem Cell Therapies for Eye Diseases
Adult Stem Cells from Skeletal Muscle and Heart - Morayma Reyes, MD, PhD
Take a closer look at adult stem cells with the University of Washington #39;s Dr. Morayma Reyes. How do these cells differ in highly regenerative tissues like skeletal muscle and poorly regenerative...
By: UWTV
Read more:
Adult Stem Cells from Skeletal Muscle and Heart - Morayma Reyes, MD, PhD - Video
Insight: Stem Cells -- Perry and Matt
Perry Cross and Matt Battista share their experiences trying highly experimental stem cell therapy to treat a spinal cord injury. Catch the full episode on Tuesday, July 15 at 8:30pm AEST on...
By: Insight SBS